The purpose of this study is to describe the treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs of lower-risk myelodysplastic syndromes patients in Japan.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Participant age
Timeframe: At date of diagnosis
Participant sex
Timeframe: At date of diagnosis
Participant weight
Timeframe: At date of diagnosis
Participant height
Timeframe: At date of diagnosis
Participant comorbidities calculated using the Charlson Comorbidity Index (CCI) method
Timeframe: From 30 days prior to diagnosis up to 7 days post to diagnosis
Participant Eastern Cooperative Oncology Group (ECOG) score
Timeframe: From 30 days prior to diagnosis up to 7 days post to diagnosis
Participant International Prognostic Scoring System (IPSS) or Revised International Prognostic Scoring System (IPSS-R) risk category
Timeframe: Date of diagnosis, 6-months and 12 months post-diagnosis
Percentage of ring sideroblasts present in participants
Timeframe: Date of bone marrow test; from 30 days prior to diagnosis up to 7 days post to diagnosis
Percentage of bone marrow blasts present in participants
Timeframe: From 30 days prior to diagnosis up to 7 days post to diagnosis
Histopathology results
Timeframe: From 30 days prior to diagnosis up to 7 days post to diagnosis
Number of red-blood cell transfusions received by participants
Timeframe: Up to 56 days post diagnosis
Treatment prescribed by line of therapy
Timeframe: From date of diagnosis, up to 5-years
Duration of treatment by line of therapy
Timeframe: From date of diagnosis, up to 5-years
Time between date of diagnosis and treatment
Timeframe: From date of diagnosis to treatment initiation
Time between date of treatment initiation to treatment discontinuation
Timeframe: Date of treatment initiation, up to 5-years
Time between date of diagnosis to date of first red-blood cell transfusion
Timeframe: Date of diagnosis, up to 5-years